Tumor lysis syndrome
Tumor Lysis Syndrome
Tumor lysis syndrome (pronunciation: TOO-mor LIE-sis SIN-drome) is a serious and potentially life-threatening disorder that can occur after treatment of cancer, particularly in cases of lymphoma and leukemia.
Etymology
The term "tumor lysis syndrome" is derived from the Latin tumor meaning "swelling", the Greek lysis meaning "loosening, destruction" and syndrome from the Greek syndromē meaning "concurrence of symptoms, concourse".
Definition
Tumor lysis syndrome is characterized by a series of metabolic disturbances that result from the rapid release of intracellular components into the bloodstream following the lysis, or destruction, of tumor cells. These disturbances can include hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia.
Related Terms
- Hyperkalemia: An abnormally high level of potassium in the blood.
- Hyperphosphatemia: An abnormally high level of phosphate in the blood.
- Hyperuricemia: An abnormally high level of uric acid in the blood.
- Hypocalcemia: An abnormally low level of calcium in the blood.
- Lymphoma: A type of cancer that begins in the cells of the lymphatic system.
- Leukemia: A type of cancer that affects the blood and bone marrow.
Treatment
Treatment of tumor lysis syndrome typically involves addressing the metabolic disturbances and preventing further cell lysis. This can include the administration of intravenous fluids, medications to control serum potassium and phosphate levels, and medications to reduce uric acid levels. In severe cases, dialysis may be required.
See Also
External links
- Medical encyclopedia article on Tumor lysis syndrome
- Wikipedia's article - Tumor lysis syndrome
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski